

PORTFOLIO MANAGERS



Caroline Cai, CFA  
With Pzena since 2004  
In Industry since 1998



John P. Goetz  
With Pzena since 1996  
In Industry since 1979



Ben Silver, CFA  
With Pzena since 2001  
In Industry since 1988

PERFORMANCE SUMMARY - AUD

	1M	QTD	One Year	Since Inception 1/30/2020
Pzena Global Focused Value Fund (Wholesale) (gross of fees)	-1.24%	-1.24%	6.19%	6.50%
Pzena Global Focused Value Fund (Wholesale) (net)	-1.27%	-1.27%	5.46%	5.75%
MSCI ACWI Index	-2.79%	-2.79%	2.78%	5.72%
MSCI ACWI Value Index	0.34%	0.34%	9.00%	3.67%

The above performance numbers are based on unaudited financial statements. The MSCI ACWI Index is used as a benchmark to indicate the investment environment existing during the time periods shown in this report. The MSCI ACWI Index is a free float-adjusted market capitalization index that is designed to measure developed market equity performance, including the U.S. and Canada and is net of withholding tax. The MSCI ACWI Index cannot be invested in directly. The Pzena Global Focused Value Fund return reflects month end valuations as at the last business day of each month and the Since Inception returns are annualised. Past performance is not necessarily an indicator of future performance.

PORTFOLIO CHARACTERISTICS

	Global Focused Value Fund	MSCI ACWI Index
Price / Earnings (1-Year Forecast)	9.5x	15.6x
Price / Book	1.1x	2.8x
Median Market Cap (A\$B)	\$40.9	\$14.8
Weighted Average Market Cap (A\$B)	\$74.2	\$466.5
Active Share	96.4	-
Number of Stocks	50	2,937

Source: MSCI ACWI Index, Pzena Analysis

FUND FACTS

Responsible Entity	Equity Trustees Limited
Inception Date	January 30, 2020
APIR	ETL0484AU
ARSN	613 118 522
Base Currency	AUD
Minimum Investment Amount	A\$1 Million
Fund AUM	A\$47.4 Million
Management Expense Ratio	0.85%
Liquidity	Daily
Benchmark Index	MSCI ACWI Index
Investment Universe	2,000 largest global companies
# of Positions	Generally 40-60
Buy/Sell Spread	0.30%/0.20%

Registered for distribution in Australia and New Zealand

ENQUIRIES

Paul Whympers-Williams

Director of Business Development and Client Services  
+61 (0)421 915 366  
whympers-williams@pzena.com

David Taylor


Principal  
Director of Business Development and Client Services  
+61 (0)409 544 513  
taylor@pzena.com

REGION CONCENTRATION



Country weights adjusted for cash - may appear higher than actual.

SECTOR WEIGHTS



Sector weights adjusted for cash - may appear higher than actual. Numbers may not add due to rounding.

For unit pricing visit: [www.eqf.com.au/insto](http://www.eqf.com.au/insto)



TOP 10 HOLDINGS

Table with 2 columns: Company Name and Percentage. Includes General Electric Company (3.5%), Westinghouse Air Brake Tech Corp (3.2%), Komatsu Ltd. (3.2%), Michelin SCA (3.2%), Edison International (3.1%), Shell PLC (3.1%), Lear Corporation (2.8%), Halliburton Company (2.8%), Newell Brands Inc (2.7%), and BASF SE (2.6%). Total: 30.2%

Numbers may not add due to rounding.

PLATFORMS

Table with 2 columns: Platform Name and Description. Includes BT Panorama, Hub24, Macquarie Wrap, Netwealth, Powerwrap, Praemium, and Xplore Wealth.

INVESTMENT PROCESS

- Universe: 2,000 largest global companies
Fundamental research conducted on companies considered the most undervalued based on price relative to normalized earnings
Co-Portfolio Managers construct a portfolio of deeply undervalued businesses requiring unanimous consent



PORTFOLIO COMMENTARY - APRIL 2022

As the war and humanitarian crisis in Ukraine dragged on throughout April, markets became increasingly concerned about the economic consequences, especially for Europe (with its high dependency on Russian energy exports). After rising by one-third in the first quarter of 2022, the oil price (WTI basis) rose a further 5% in April, remaining above \$100 per barrel. Elevated energy costs and ongoing supply chain disruptions kept pressure on the inflation data as long bonds backed up again in yield, with 10-year Treasury bond yields rising by almost 60bps in the month to 2.9%.

Equity markets around the world closed lower with MSCI All Country World Index (in local currency terms) posting a -6.5% return for the month (with the ACWI Value Index again outperforming at -3.5%). Only in emerging markets did the Value Index finally trail the broader market, slightly, (-3.6% versus -3.5%). The US stock market fared worst as some of the large cap. growers disappointed and corrected sharply, with rising interest rates pressuring their elevated valuation levels.

The Australian dollar lost 5.4% against the strong US dollar. As a result, in Australian dollar terms, the MSCI All Country World Index recorded a -2.8% return (and its Value counterpart +0.3%). The Pzena Global Focused Value portfolio returned -1.2% for the month. Our stock selection in information technology (including what was not owned), consumer discretionary and financials contributed to relative performance.

At the stock level, three of the top relative contributors included Newell Brands, Avnet and McKesson Corporation. Investors bought up shares of Newell Brands, betting that inflation would provide a tailwind. Newell did indeed report a solid set of results at the end of the month, with all five of its segments coming in ahead of the Street's expectations with strong sales and solid margins.

Three of the top relative detractors during the month included General Electric Company, Baker Hughes and Lear Corporation. General Electric was down after reporting disappointing 1Q2022 results due to continued supply chain issues. The company is not seeing an easing of these issues in 2Q but does expect sequential improvement in earnings over the course of the year as actions to offset, including pricing, flow through.

Lear was down in April on a few broker downgrades, as the Street remains concerned over cost inflation impacting the company's margins, inflation which we believe can be passed through to its customers, albeit with a time lag. We continued to add to our positions in Fresenius Medical Care (healthcare company) and Nokia (wireless telecom networking equipment) during the month.

The estimated weighted average price to normal earnings ratio of the portfolio is 8.8x compared to the estimated universe median price to normal earnings ratio of 14.4x.

## DISCLOSURES

This document has been prepared and issued by Pzena Investment Management, LLC (ARBN 108 743 415), a limited liability company ("Pzena"). Pzena is regulated by the Securities and Exchange Commission (SEC) under U.S. laws, which differ from Australian laws. Pzena is exempt from the requirement to hold an Australian financial services license in Australia in accordance with ASIC Corporations (Repeal and Transitional) Instrument 2016/396. Pzena offers financial services in Australia to 'wholesale clients' only pursuant to that exemption. This document is not intended to be distributed or passed on, directly or indirectly, to any other class of persons in Australia.

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Pzena Global Focused Value Fund ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EOT). The Investment Manager for the Fund is Pzena Investment Management, LLC (ARBN 108 743 415) ("Pzena"). This publication has been prepared by Pzena to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Equity Trustees, Pzena nor any of their related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accept any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. The Fund's Target Market Determination is available here <https://www.eqt.com.au/insto/>. A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.

In New Zealand, any offer of this Wholesale Class of the Fund is limited to 'wholesale investors' within the meaning of clause 3(2) of Schedule 1 of the Financial Markets Conduct Act 2013 ('FMCA'). This document is not to be treated as an offer, and is not capable of acceptance by, any person in New Zealand who is not a Wholesale Investor.

While information contained in this document has been prepared with all reasonable care, no responsibility or liability is accepted by Pzena for any errors or omissions or misstatements however caused. The information contained herein is not an indication of future performance of the Fund. Information provided herein is general information only and does not take account of your personal objectives, financial situation or needs. Accordingly, you should obtain financial advice to ascertain the suitability of our products for their personal financial needs and circumstances. You should also consider information in the Product Disclosure Statement ("PDS") and Reference Guide before making a decision about investing in the Fund.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned August 2020) referred to in this document is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>

© Pzena Investment Management, LLC, 2022. All rights reserved.